Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

s compared to placebo.

"The results of the MERLIN TIMI-36 study confirm that ranolazine is a safe and effective anti-ischemic drug that also has favorable effects on arrhythmia and HbA1c," Morrow said. "The reduction in HbA1c observed with ranolazine in the MERLIN TIMI-36 study is especially striking because the effects were observed on top of multiple other anti-diabetic drugs used as part of standard therapy."

In accordance with a special protocol assessment agreement between the U.S. Food and Drug Administration (FDA) and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina. In September 2007, the Company submitted a supplemental new drug application to the FDA seeking a new indication for first line angina and a significant reduction in cautionary language.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatment. The doses of Ranexa extended-release tablets used in MERL
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/mp95jv/global_hearing ) has ... Aids Market 2015-2019" report to their offering. ... to grow at a CAGR of 4.68% during ... as changing demographics and high prevalence of hearing ... witnessed immense technological advances. These factors, combined with ...
(Date:7/28/2015)... 2015 The Canadian International Pharmacy ... Canadian Anti-Fraud Centre (CAFC), continues to aggressively ... CIPA verification seal on illegitimate pharmacy websites.  The ... pharmacy member companies who have maintained a 100% ... than 10 million Americans since 2002. ...
(Date:7/28/2015)... July 28, 2015   Cynosure, Inc. ... markets medical devices for aesthetic procedures and precision ... the three months ended June 30, 2015. ... of double-digit growth, as revenues increased 47 percent ... Chief Executive Officer Michael Davin. "While our international ...
Breaking Medicine Technology:Global Hearing Aids Market 2015-2019 with G N Store Nord, Sonova Holdings & William Demant Dominating 2Canadian International Pharmacy Association (CIPA) Continues to Fight Rogues Fraudulently Using the Trusted CIPA Verification Seal 2Canadian International Pharmacy Association (CIPA) Continues to Fight Rogues Fraudulently Using the Trusted CIPA Verification Seal 3Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 2Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 3Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 4Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 5Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 6Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 7Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 8Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 9Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 10Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 11Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 12Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 13
... presented at 2008 ICAAC/IDSA Joint Meeting, ... a,clinical-stage biopharmaceutical company focused on commercializing,products to ... the,successful demonstration of synergistic activities and improvement ... vitro combination,studies of Sequella lead TB drug ...
... PharmAthene, Inc.,(NYSE ALTERNEXT US: PIP), a biodefense ... today announced,that dosing of volunteers has begun in ... safety and tolerability in humans. Protexia(R),which is produced ... recombinant version,of human butyrylcholinesterase (BChE), which has been ...
Cached Medicine Technology:Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 2PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 3PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 4PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 5
(Date:7/28/2015)... ... July 28, 2015 , ... Mindful Her, a unique women’s wellness and ... healthy and mindful living practices to the next level, announced today an influential line-up ... Intent as keynote. Global Girls, an Orange County based non-profit that works locally ...
(Date:7/28/2015)... Savannah, Tenn. (PRWEB) , ... July 28, 2015 ... ... span July through October this year, as volunteers celebrate the 14th year of ... Morgan and Tracy Lawrence in downtown Savannah for this year’s main concert Saturday, ...
(Date:7/28/2015)... TX (PRWEB) , ... July 28, 2015 , ... ... announce the arrival of Dr. Sudeep Roy in July 2016. Coming to Austin ... surgery with Dr. Buckingham. The twelve-month long training is facilitated annually by the ...
(Date:7/28/2015)... California (PRWEB) , ... July 28, 2015 , ... ... results from a recent survey (1) examining consumers’ perspectives on digital health ... 17-24, 2015, covered topics such as innovations in digital health, level of trust in ...
(Date:7/28/2015)... ... July 28, 2015 , ... opaJUMP! ... measure and produce health outcomes associated with its training methods. This company is ... small group pre-post study, conducted in early 2015, training yielded an average 80% ...
Breaking Medicine News(10 mins):Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 2Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 3Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 2Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 3Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 2Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 4Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 2Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 6Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 7
... model that looks at different strategies for curbing ... isolation may be effective approaches when patients are ... superbugs, such as methicillin-resistant Staphylococcus aureas (MRSA), and ... infections, this type of modeling, if used to ...
... problem that needs to be addressed next is the epidemic ... together to discuss the latest in pain research and treatment ... Pain Medicine (AAPM), February 12-16 at the Gaylord Palms in ... help of their physicians, have been asked to stop smoking ...
... otherwise healthy people have similar survival rates to younger ... older patients can undergo lung transplantation and have good ... patients from having the procedure, a new study says. ... Medical Center reviewed the records of 48 UCLA patients ...
... Proposed Changes in ... Lifesaving Effort, WASHINGTON, Feb. 16 As President Bush ... funded by the,President,s Emergency Plan for AIDS Relief (PEPFAR), the ... request, AIDS Healthcare,Foundation (AHF) ( http://www.aidshealth.org ) today cautioned the ...
... release is also available in French . ... flushing toxic chemicals into the ecosystem through municipal sewer ... comes from an unlikely source: estrogen. , After an ... amounts of estrogen present in municipal wastewater discharges can ...
... Crowder &,DeGaris, P.C. (http://www.cwcd.com ), has filed ... the United States, who allegedly suffered,permanent kidney damage ... to prevent excessive bleeding during coronary,artery bypass graft ... to CBS News, 60 Minutes will report Sunday ...
Cached Medicine News:Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2Health News:Physicians focus on stopping pain epidemic 2Health News:Physicians focus on stopping pain epidemic 3Health News:Physicians focus on stopping pain epidemic 4Health News:Physicians focus on stopping pain epidemic 5Health News:Physicians focus on stopping pain epidemic 6Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:Bush AIDS Legacy at Risk, Says AHF 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 3Health News:60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG 2
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
Latex agglutination inhibition slide test for the qualitative detection of hCG in urine....
... Reagin card test for ... quantitative determination of syphilis ... Uses carbon particle cardiolipin ... Kits include 10-well cards ...
Color-enhanced slide test for the rapid qualitative and semi-quantitative detection of antibodies to streptococcal extracellular antigens in serum, plasma and peripheral blood....
Medicine Products: